• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Arestin (minocycline hydrochloride)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Arestin (minocycline hydrochloride)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Arestin (minocycline hydrochloride) is indicated for the adjunctive treatment of adult periodontitis following scaling and root planing, which consist of deep cleaning of the teeth and gums. It is painless to apply and is completely resorbed, leaving nothing to be removed. Arestin is highly bioadhesive, not requiring any retention dressings, and will not leak or fall out. The drug has been studied only in patients with chronic periodontitis.

    Periodontal disease is a vastly under treated health problem that carries serious risks. It affects more than 50 million people in the United States, though less than one-fifth of these individuals receive treatment. Studies suggest a possible systemic link between periodontal disease and overall health, including conditions such as coronary heart disease, stroke, and diabetes.

    Clinical Results

    Clinical trials testing the safety and effectiveness of the product were conducted in over 900 subjects with chronic periodontitis. These landmark trials, conducted in 23 centers across the United States, involved tens of thousands of individual periodontal pockets. Treatment using Arestin following scaling and root planing significantly reduced pocket depth compared with scaling and root planing alone, even for the hardest to treat sites and with the most challenging patients.

    Side Effects

    Adverse events associated with the general use of minocycline may include (but are not limited to) the following:


    • Nausea or diarrhea
    • Dizziness
    • Sensitivity to sun
    • "Furry" or swollen tongue

    Mechanism of Action

    Arestin uses patented microsphere technology to deliver minocycline, a tetracycline antibiotic, beneath the gum, directly into the infected periodontal pocket.

    Additional Information

    For additional information on Arestin, please visit OraPharma.

    Approval Date: 2001-02-01
    Company Name: OraPharma
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing